Document Detail


Treatment of modified Stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach.
MedLine Citation:
PMID:  6308356     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty patients with postsurgical, modified Stage II (T2 N1 M0, T1 N1 M0) non-small cell bronchogenic carcinoma were seen between 1974 and 1981 and were evaluated in a retrospective manner. Fifteen patients had T2 N1 M0 lesions, while 5 patients had T1 N1 M0 disease. Eight patients were treated with surgical resection alone, of whom seven had died, with a median survival of 12.0 months. Four patients received surgical resection and postoperative radiation therapy, of whom two have died, with a median survival not reached at 37 months. Eight patients were treated with surgical resection, radiation therapy, and adjuvant chemotherapy including cyclophosphamide (C), doxorubicin (A), methotrexate (M), and procarbazine (P). Six patients are alive and free of disease, with a median survival not yet reached at 72 months. There is a significant survival advantage for the 12 patients treated with combined modality therapy (surgical resection + radiation therapy; surgical resection + radiation therapy + chemotherapy) compared to the eight patients treated with SR alone (p less than 0.01), and for the eight patients receiving chemotherapy versus the 12 patients who did not (p less than 0.01). In spite of thorough clinical and surgical staging, patients with T1 and T2 primary tumors with N1 disease have a high relapse rate, predominantly in metastatic sites. Adjuvant radiation therapy and chemotherapy appear to benefit these patients with modified Stage II non-small cell bronchogenic carcinoma.
Authors:
S B Newman; T R DeMeester; H M Golomb; P C Hoffman; A G Little; V Raghavan
Related Documents :
6841036 - The fate of patients with lung cancer: five-year review of 250 cases.
2164056 - New trends in the surgical treatment of non-small cell lung cancer.
9451676 - Clinicopathologic features of resected primary adenosquamous carcinomas of the liver.
20805936 - Immunohistochemical examination of a resected advanced hilar cholangiocarcinoma arising...
25312386 - Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk dista...
1777606 - Modified chop in an aged patient with non-hodgkin's lymphoma and probable extensive pul...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of thoracic and cardiovascular surgery     Volume:  86     ISSN:  0022-5223     ISO Abbreviation:  J. Thorac. Cardiovasc. Surg.     Publication Date:  1983 Aug 
Date Detail:
Created Date:  1983-09-20     Completed Date:  1983-09-20     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0376343     Medline TA:  J Thorac Cardiovasc Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  180-5     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy,  radiotherapy,  surgery
Adult
Aged
Antineoplastic Agents / therapeutic use
Carcinoma, Bronchogenic / drug therapy,  radiotherapy,  surgery*
Carcinoma, Small Cell / drug therapy,  radiotherapy,  surgery
Carcinoma, Squamous Cell / drug therapy,  radiotherapy,  surgery
Drug Therapy, Combination
Female
Humans
Lung Neoplasms / drug therapy,  radiotherapy,  surgery*
Male
Middle Aged
Neoplasm Recurrence, Local
Prognosis
Retrospective Studies
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of kava on neuromuscular transmission and muscle contractility.
Next Document:  Prediction of postoperative pulmonary function following thoracic operations. Value of ventilation-p...